Silence Therapeutics plc (SLN) Financial Statements
Silence Therapeutics plc (SLN) reported trailing twelve-month revenue of $615000 (down 97.7% year on year) and net income of -$60.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$42.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SLNSilence Therapeutics plcFollow SLN — free
—
Price chart with a free account
- Market cap
- 929.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Revenue | 31.6 | 43.3 | 0.6 | 0.6 | |
| Gross profit | — | 31.4 | 0.3 | 0.5 | |
| Research & development | — | 67.9 | 67.8 | 47.6 | |
| Operating income | — | -63.3 | -91.1 | -68.3 | |
| Pre-tax income | — | -44.5 | -88.6 | -60.0 | |
| Income tax | — | 0.8 | 0.0 | 0.0 | |
| Net income | — | -45.3 | -88.6 | -60.0 | |
| Diluted EPS ($) | — | -0.33 | -0.63 | -0.44 | |
| Diluted shares (mn) | — | 138.8 | 141.7 | — |
USD millions · SEC XBRL
Silence Therapeutics plc — questions
- What is Silence Therapeutics plc's revenue?
- $615000 over the twelve months to 2026-06-30, down 97.7% year on year, from its 10-Q and 10-K filings.
- What is Silence Therapeutics plc's net income?
- -$60.0M over the twelve months to 2026-06-30.
- What is Silence Therapeutics plc's free cash flow?
- -$42.3M over the twelve months to 2026-06-30.
- What are Silence Therapeutics plc's diluted earnings per share?
- $-0.44 over the twelve months to 2026-06-30.
Every figure on this page comes from Silence Therapeutics plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.